Treatment pattern and prognosis in Japanese patients with metastatic renal cell carcinoma (mRCC) with favorable or intermediate MSKCC risk factors in the era of molecular targeted therapy.
Nobuo Shinohara
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis; Pfizer
Satoru Maruyama
No relevant relationships to disclose
Wataru Obara
No relevant relationships to disclose
Katsunori Tatsugami
No relevant relationships to disclose
Sei Naito
No relevant relationships to disclose
Tomomi Kamba
No relevant relationships to disclose
Seiji Naito
No relevant relationships to disclose